HOME-PE Trial Clarifies Which PE Patients to Treat at Home HOME-PE Trial Clarifies Which PE Patients to Treat at Home
The randomized HOME-PE trial clarifies a transatlantic controversy regarding how best to triage patients with acute pulmonary embolism for outpatient care. Hestia criteria proved as safe as sPESI score.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - September 1, 2020 Category: Internal Medicine Tags: Cardiology News Source Type: news
Hospitalized COVID-19 Patients and Venous Thromboembolism Hospitalized COVID-19 Patients and Venous Thromboembolism
Early reports indicate that a very high proportion of critically ill patients hospitalized with COVID-19 will experience venous thromboembolism, particularly pulmonary embolism.Circulation (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - August 28, 2020 Category: Radiology Tags: Infectious Diseases Journal Article Source Type: news
Finer Risk Stratification Key in Acute Pulmonary Embolism Finer Risk Stratification Key in Acute Pulmonary Embolism
Patients with intermediate- to low-risk PE, and those with low-risk PE, require anticoagulation only. In contrast, patients with intermediate- to high-risk PE are at increased risk of decompensation.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - August 19, 2020 Category: Internal Medicine Tags: Hospital Medicine News Source Type: news
Embelin ameliorated sepsis-induced disseminated intravascular coagulation intensities by simultaneously suppressing inflammation and thrombosis
In this study, we used three thrombotic mice models to confirm the antithrombotic property of embelin. By combining the anti-inflammatory and the antithrombotic properties, we proposed embelin as a potent therapeutic agent for sepsis-induced DIC, which involves both inflammation and thrombosis. In a lipopolysaccharides-induced septic mice model, embelin not only significantly ameliorated the inflammation levels, but also effectively reduced the pulmonary hemorrhages and the micro-thrombi formations in lung. In contrast, low-molecular-weight-heparin, an anticoagulant, only moderately ameliorated the pulmonary hemorrhages an...
Source: Current Awareness Service for Health (CASH) - August 5, 2020 Category: Consumer Health News Source Type: news
What Are Some Pediatric Oncological Emergencies?
Discussion
Pediatric cancers in the US number about 12,000 per year. After injury, it is the second leading cause of death in children and adolescents. Cancer presentations vary widely, but often begin with non-specific symptoms that continue or progress depending on the location and tumor type. Patients can present with oncological emergencies especially if there are mechanical obstruction such as superior vena cava syndrome or cerebral herniation. More commonly are infections due to immunosuppression. Cancer treatment also causes its own myriad of problems that clinicians need to be aware of to diagnosis and treat, but a...
Source: PediatricEducation.org - July 20, 2020 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news
Alembic Pharma gets tentative USFDA nod for generic Rivaroxaban tablets
Rivaroxaban tablets are indicated for multiple conditions, including reduction of risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation; treatment of deep vein thrombosis (DVT) and treatment of pulmonary embolism (PE). (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - June 21, 2020 Category: Pharmaceuticals Source Type: news
Barriers exist to using risk stratification tools to evaluate pulmonary embolism in the ED
(Society for Academic Emergency Medicine) Common barriers exist to the use of risk stratification tools in the evaluation of pulmonary embolism in the emergency department and provide insight into where to focus efforts for future implementation endeavors. That is the conclusion of a study to be published in the June 2020 issue of Academic Emergency Medicine (AEM), a journal of the Society for Academic Emergency Medicine (SAEM). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 15, 2020 Category: International Medicine & Public Health Source Type: news
DoD Funds Clinical Trial of Seraph Blood Filter to Treat COVID-19
The Department of Defense is funding a clinical trial of a COVID-19 treatment using ExThera Medical’s Seraph 100 Blood filter.
The device was selected to be in the multi-center randomized clinical trial because it showed encouraging preliminary results in critically ill COVID-19 patients at a military hospital in the U.S. and 14 other hospitals in Europe. Investigators at the Uniformed Services University in Bethesda will run the trial of the Martinez, CA-based company’s device. Initial reports indicate Seraph 100 stabilizes blood pressure and inflammatory biomarkers that correlate with ...
Source: MDDI - June 10, 2020 Category: Medical Devices Authors: Omar Ford Tags: COVID-19 Business Source Type: news
Devices Will Play A Greater Role in COVID-19
Up until now, medical devices have been in the background when it comes to the novel coronavirus. The bigger stories in the industry came from diagnostic firms either developing virus detection or antibody tests.
Â
However, that all changed when Danvers, MA-based Abiomed was granted Emergency Use Authorization for the Impella RP to include patients suffering from COVID-19 related right heart failure or decompensation, including pulmonary embolism.
Â
I give my take on why this lone EUA could be the start of more device-related solutions regarding symptoms associated with COVID-19.
Â
&Acir...
Source: MDDI - June 8, 2020 Category: Medical Devices Tags: COVID-19 Source Type: news
Abiomed Granted IDE to Evaluate ‘World’s Smallest Heart Pump’
Abiomed said it has received approval for an IDE to start an early feasibility study of what it is calling the “world’s smallest heart pump.â€
Â
The Danvers, MA-based company said the first-in-human trial will look at the 9 French Impella ECP heart pump in high-risk percutaneous coronary intervention (PCI) patients.
Â
The primary endpoint of the study is successful delivery, initiation, and maintenance of adequate hemodynamic support and a composite rate of major device-related adverse events during high-risk PCI.
Â
The stu...
Source: MDDI - June 6, 2020 Category: Medical Devices Tags: Cardiovascular Regulatory and Compliance Source Type: news
Thrombosis in COVID-19: clinical outcomes, biochemical and pathological changes, and treatments, CEBM
Reports that COVID-19 is associated with venous and arterial thrombosis and pulmonary embolism and increased rates of thrombosis in cannulae and extracorporeal circuits for renal replacement or membrane oxygenation, have drawn attention to the coagulant effects of the disease. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - June 4, 2020 Category: Consumer Health News Source Type: news
Pulmonary embolism and COVID-19
(Henry Ford Health System) Researchers at Henry Ford Health System in Detroit say early diagnosis of a life-threatening blood clot in the lungs led to swifter treatment intervention in COVID-19 patients. In a new study published recently in the journal Radiology, researchers found that 51 percent of patients found to have a pulmonary embolism, or PE, were diagnosed in the Emergency Department, the entry point for patients being admitted to the hospital. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - June 2, 2020 Category: Infectious Diseases Source Type: news
New EUA Places Abiomed Firmly in the COVID-19 Conversation
Sometimes when the discussion of tackling the novel coronavirus comes up, the use of medical devices gets lost in the shuffle. Most of the conversation surrounding COVID-19 comes from either the promise of a vaccine or the expansion of tests.
Abiomed is adding to the conversation surrounding medtech’s potential contribution to the treatment of COVID-19 patients. Monday, the Danvers, MA-based company by receiving Emergency Use Authorization for a device to treat COVID-19 related right heart failure patients.
The Impella RP is a temporary heart pump that provides circulatory support for patients who develop...
Source: MDDI - June 2, 2020 Category: Medical Devices Authors: Omar Ford Tags: Cardiovascular COVID-19 Source Type: news
FDA Issues Emergency Use Authorization for Impella RP in COVID-19 FDA Issues Emergency Use Authorization for Impella RP in COVID-19
The authorization allows use of the temporary heart pump in the treatment of right heart failure or decompensation, including pulmonary embolism, caused by COVID-19 complications.FDA Approvals (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - June 1, 2020 Category: Cardiology Tags: Cardiology News Alert Source Type: news
Odds of Pulmonary Embolism Up for Obese COVID - 19 Patients
Odds of developing PE lower for COVID - 19 patients taking statin therapy prior to admission (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - May 20, 2020 Category: Respiratory Medicine Tags: Infections, Pulmonology, Radiology, Critical Care, Emergency Medicine, Journal, Source Type: news
